Condition: Prevention of Rejection in Kidney Transplant · Sponsor: Eledon Pharmaceuticals
This study will evaluate the safety, PK, and efficacy of AT 1501 in patients undergoing kidney transplantation.
This description comes directly from the study's public registry record.
Eledon Pharmaceuticals · 949-238-8090 · clinicaltrials@eledon.com
Always discuss trial participation with your own doctor first.
| University of Cincinnati | Cincinnati, Ohio, United States | Recruiting |
| Royal Prince Alfred Hospital | Camperdown, New South Wales, Australia | Recruiting |
| Royal Adelaide Hospital | Adelaide, South Australia, Australia | Recruiting |
| Fundação Oswaldo Ramos - Hospital do Rim | São Paulo, Brazil | Recruiting |
| Providence Health Care - St. Paul's Hospital | Vancouver, British Columbia, Canada | Recruiting |
| Vancouver General Hospital | Vancouver, British Columbia, Canada | Recruiting |
| McGill University Health Care Centre | Montreal, Quebec, Canada | Recruiting |
| Liverpool University Hospitals NHS Foundation Trust - Royal Liverpool University Hospital | Liverpool, United Kingdom | Recruiting |
| Oxford University Hospitals NHS Foundation Trust - John Radcliffe Hospital | Oxford, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05027906